1. Home
  2. NMG vs TTRX Comparison

NMG vs TTRX Comparison

Compare NMG & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nouveau Monde Graphite Inc.

NMG

Nouveau Monde Graphite Inc.

HOLD

Current Price

$0.88

Market Cap

300.1M

ML Signal

HOLD

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$10.03

Market Cap

298.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMG
TTRX
Founded
2011
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
300.1M
298.8M
IPO Year
2015
2025

Fundamental Metrics

Financial Performance
Metric
NMG
TTRX
Price
$0.88
$10.03
Analyst Decision
Buy
Strong Buy
Analyst Count
8
2
Target Price
$3.62
★ $25.00
AVG Volume (30 Days)
★ 477.2K
90.0K
Earning Date
11-11-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$900.00
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$2.57
52 Week High
$3.60
$16.45

Technical Indicators

Market Signals
Indicator
NMG
TTRX
Relative Strength Index (RSI) 17.04 38.98
Support Level N/A $9.02
Resistance Level $2.42 $10.72
Average True Range (ATR) 0.05 0.89
MACD -0.01 -0.27
Stochastic Oscillator 5.25 7.76

Price Performance

Historical Comparison
NMG
TTRX

About NMG Nouveau Monde Graphite Inc.

Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: